SuperworthEntrada Therapeutics market cap TRDA
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $171.7M
- Highest close in our data
- $807.9M
- Dec 2024
Entrada Therapeutics is worth $171.7M at the close on Oct 23, 2026, at $4.41 a share.
That is down 34% over the last year and down 73% over five years.
Its highest close in our data was $807.9M in Dec 2024.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $171.7M | $170.2M | $555.1M | −57% |
| 2025 | $397.9M | $197.4M | $685.2M | −39% |
| 2024 | $651.5M | $408.3M | $807.9M | +29% |
| 2023 | $503.5M | $333.8M | $573.6M | +19% |
| 2022 | $424.6M | $176.3M | $710.5M | −21% |
| 2021 | $534.4M | $479.1M | $631.7M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Entrada Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| TRDAEntrada Therapeutics | $171.7M |
| NATRNatures Sunshine Products | $213.8M |
| LFVNLifevantage | $73.4M |
| SPROSpero Therapeutics | $64.6M |
| ARVNArvinas | $477.3M |
| PBYIPuma Biotechnology | $568.9M |
| IRWDIronwood Pharmaceuticals | $571.7M |
| ZVRAZevra Therapeutics | $582.6M |
| CRMDCorMedix | $611.9M |
| ATNMActinium Pharmaceuticals | $47.8M |
| COLLCollegium Pharmaceutical | $747.5M |
| Peer median | $523.1M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Entrada Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.